Novo Nordisk Enjoys Obesity Sales Boost Despite Wegovy Supply Issues
Reports 82% Growth In Q3
Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.
Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.